Showing results (81-90 of 166) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2023
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)Ernest Nadal, Delvys Rodríguez-Abreu, Marta Simó, et al.
Molecular Cancer|May 29, 2026
NSCLC brain metastases exhibit reduced HLA-I antigen presentation machinery and immune evasion independent of IFNγ signaling defectsNoelia Vilariño, Miguel López de Rodas, Maria Villalba-Esparza, et al.
Nature Medicine|February 9, 2016
Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinomaChiara Ambrogio, Gonzalo Gómez-López, Mattia Falcone, et al.
Cancer Research|September 14, 2014
Modeling lung cancer evolution and preclinical response by orthotopic mouse allograftsChiara Ambrogio, Francisco J Carmona, August Vidal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 30, 2024
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus ChemotherapyMaximilian Hochmair, Michael Schenker, Manuel Cobo Dols, et al.
Cell Death & Disease|March 30, 2026
Antagonistic SMAD2/3 control of TIMP-1, VEGF-A, and hypoxia signaling in myofibroblasts shapes histotype-specific angiogenesis in lung cancerNatalia Díaz-Valdivia, Paula Duch, Rafael Ikemori, et al.
Translational Lung Cancer Research|August 25, 2021
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapyXuanye Zhang, Dan Tian, Yue Chen, et al.
BMC Cancer|July 28, 2023
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancerErnest Nadal, Mansoor Saleh, Santiago Ponce Aix, et al.
Nature Medicine|August 12, 2022
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trialVivek Subbiah, Philippe A Cassier, Salvatore Siena, et al.
Nature Communications|June 24, 2020
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumoursJoão M Fernandes Neto, Ernest Nadal, Evert Bosdriesz, et al.
Pageof 17